AbbVie, Calico Extend Their Collaboration On Aging
Executive Summary
The pharma and the Google spinout focused on aging are adding $1bn in funding to their 2014 collaboration, which has yielded more than two dozen preclinical candidates so far.
You may also be interested in...
Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
AbbVie Explores Uncharted Territory With DUB Inhibitor Neuroscience Deal
AbbVie has added Mission Therapeutics to its preclinical partnership roster with a neurology deal to develop DUB inhibitors in Alzheimer’s and Parkinson’s disease.
Private Longeveron Bets On Stem Cells For Inflammation, Aging Diseases
Emerging Company Profile: The start-up's Phase I and II studies look promising for stem cell therapy in treating aging frailty, a common condition that overlaps with Alzheimer's disease.